Approved comparison material connected to this topic.
15 total recordsSource comparisons are presented without a generated winner.
Research objectives determine dosing strategy. The table below compares protocols used in published studies and institutional research settings, categorized by experimental focus. Acute anabolic signaling assa…
The table below compares three research-standard IGF-1 LR3 dosing protocols used in 2026 hyperplasia studies, showing dose structure, cycle design, and projected receptor preservation. Conservative Split-Dose …
Acute Signaling Study 80–120mcg Twice daily (split dose) 1–7 days Maximal Akt/mTOR activation within 2–4 hours; 2–3× baseline protein synthesis rates Low (insufficient time for significant downregulation) Idea…
Rodent systemic IGF-1 5–20 mg/day Intraperitoneal infusion 8–12 weeks continuous 15–30% increase in fiber number; myonuclear addition confirmed via histology Gold standard for hyperplasia research; not replica…
Before selecting a dosing strategy, understanding how different protocols perform across key variables. Dose range, injection frequency, nutrient timing, and expected outcomes. Provides context for matching pr…
Conservative Titration 20–40mcg Subcutaneous (abdominal) Non-specific 4–6 weeks Lowest side effect risk; slower hypertrophy rate; suitable for baseline sensitivity assessment Standard Research Range 40–80mcg I…
The table below compares standard recovery dosing protocols across different research applications. Each protocol is calibrated for specific recovery contexts. Acute injury, post-surgical rehabilitation, train…
The following table presents weight-adjusted dosing ranges used in published IGF-1 LR3 research across species, along with the metabolic rationale and typical reconstitution volumes for each model. The bottom-…
IGF-1 LR3 20–30 hours Minimal (modified E-domain) High (direct IGF-1R agonism) 20–80mcg daily Receptor saturation above 60mcg Endogenous IGF-1 10–12 minutes >95% bound in circulation Low (limited bioavailabili…
20mcg daily Fasted state (10+ hours), pre-workout 4–8 weeks 0.8–1.2 kg fat mass reduction Minimal; occasional transient hypoglycemia (<5% subjects) Effective threshold dose for measurable substrate shift; lowe…
20–40 mcg/day Moderate. Detectable proliferation markers, gradual strength/recovery gains Minimal glucose metabolism changes, low hypoglycemia risk Injury recovery models, older populations, conservative titra…
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of endogenous IGF-1, modified at the third position of the N-terminal domain to prevent binding to IGF-binding proteins (IGFBPs). The seru…
20–30mcg daily 60–70% saturation Insulin-sensitive subjects, high training frequency, first-time protocols Mild glucose disposal (+15–20% uptake) Low (5–10% of subjects) Optimal starting point for metabolicall…
Two injection strategies exist, and they change where you place the needle, not the calculation. Systemic dosing puts the full daily dose into a single subcutaneous site, usually the abdomen, to raise circulat…
A U-100 insulin syringe is marked in "units," not milliliters. On a U-100 scale, 100 units equals 1 mL, so 1 unit equals 0.01 mL. The entire barrel of a 1 mL syringe runs from 0 to 100 units. This is the singl…